Some common single-nucleotide polymorphisms (SNP) in the coding regions of the FcgRIIIa and FcgRIIa genes have been associated with differential mAb-binding affinities and clinical outcomes. In their study (1), Liu and colleagues performed a validation of these polymorphisms in a randomized trial of cetuximab (anti-EGFR mAb) monotherapy in metastastic colorectal cancer (mCRC).
Negri, F.v., Boggiani, D., Rimanti, A., Musolino, A. (2016). FCGR, Cetuximab, and Colorectal Cancer Survival-Letter. CLINICAL CANCER RESEARCH, 1, 4958-4958.
FCGR, Cetuximab, and Colorectal Cancer Survival-Letter
MUSOLINO A
Ultimo
2016
Abstract
Some common single-nucleotide polymorphisms (SNP) in the coding regions of the FcgRIIIa and FcgRIIa genes have been associated with differential mAb-binding affinities and clinical outcomes. In their study (1), Liu and colleagues performed a validation of these polymorphisms in a randomized trial of cetuximab (anti-EGFR mAb) monotherapy in metastastic colorectal cancer (mCRC).File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
